<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485835</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00049962</org_study_id>
    <secondary_id>WCI2005-11/MMRC037</secondary_id>
    <nct_id>NCT01485835</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Multiple Myeloma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, that ganetespib and&#xD;
      bortezomib has on you and your cancer. The investigators will determine the side effects of&#xD;
      different dose levels of ganetespib when given alone and the effect it has on your cancer&#xD;
      alone. The investigators will also determine the side effects of ganetespib at different dose&#xD;
      levels when given in combination with bortezomib and the effect the combination has on your&#xD;
      cancer. The study will measure levels of the drug in your blood and bone marrow as well.&#xD;
&#xD;
      Bortezomib is a proteasome inhibitor that is approved by the US Food and Drug Administration&#xD;
      (FDA) that is used for the treatment of multiple myeloma. The brand name for bortezomib is&#xD;
      Velcade®.&#xD;
&#xD;
      Ganetespib is considered &quot;investigational&quot; because it has not received approval from the Food&#xD;
      and Drug Administration for general use, although it has been previously tested in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of ganetespib in combination with bortezomib and dexamethasone.</measure>
    <time_frame>30 days after final cycle</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ganetespib + Bortezomib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks&#xD;
Cohort 1: 100 mg/m²&#xD;
Cohort 2: 100 mg/m²&#xD;
Cohort 3: 120 mg/m²&#xD;
Cohort 4: 144 mg/m²&#xD;
Cohort 5: 173 mg/m²&#xD;
Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks&#xD;
Cohort 1: 1.0 mg/m²&#xD;
Cohort 2, 3, 4, 5: 1.3 mg/m²&#xD;
Dexamethasone: Oral prior to bortezomib&#xD;
Cohort 1, 2, 3, 4, 5: 20 + 20 mg&#xD;
Day of and following bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganetespib</intervention_name>
    <description>Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.</description>
    <arm_group_label>Ganetespib + Bortezomib + Dexamethasone</arm_group_label>
    <other_name>STA-9090</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.</description>
    <arm_group_label>Ganetespib + Bortezomib + Dexamethasone</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.</description>
    <arm_group_label>Ganetespib + Bortezomib + Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, age 18 years or older.&#xD;
&#xD;
          -  Diagnosis of relapsed or refractory multiple myeloma (MM) and documentation of at&#xD;
             least 2 prior therapies which must have included bortezomib and an immunomodulatory&#xD;
             agent; there is no maximum number of prior regimens.&#xD;
&#xD;
          -  Patients with measurable disease defined as at least one of the following:&#xD;
&#xD;
               1. Serum M-protein ≥ 0.5 g/dl (≥ 5 g/l)&#xD;
&#xD;
               2. Urine M-protein ≥ 200 mg/24 h&#xD;
&#xD;
               3. Serum free light-chain (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l)&#xD;
                  and an abnormal serum free light chain ratio (&lt; 0.26 or &gt; 1.65)&#xD;
&#xD;
               4. Measurable plasmacytoma (prior biopsy is acceptable, should be measured within 28&#xD;
                  days of first study drug administration).&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group (ECOG) ≤ 2 OR Karnofsky ≥ 60%&#xD;
             performance status.&#xD;
&#xD;
          -  Females of childbearing potential*: Confirmation that the subject is not pregnant must&#xD;
             be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy&#xD;
             test result obtained during screening. Pregnancy testing is not required for&#xD;
             post-menopausal or surgically sterilized women. FCBP must also agree to ongoing&#xD;
             pregnancy testing. Men must agree to use a latex condom during sexual contact with a&#xD;
             FCBP even if they have had a successful vasectomy. *(FCBP - A female of childbearing&#xD;
             potential is a sexually mature woman who: 1) has not undergone a hysterectomy or&#xD;
             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24&#xD;
             consecutive months).&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information (in accordance&#xD;
             with national and local subject privacy regulations).&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of routine medical care with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          -  Inclusion clinical laboratories criteria&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 10⁹/L) (Growth factors&#xD;
                  cannot be used within 7 days of first drug administration)&#xD;
&#xD;
               2. Platelet count ≥ 75 x 10⁹/L (platelet transfusions cannot be used within 4 days&#xD;
                  of first drug administration)&#xD;
&#xD;
               3. Hemoglobin ≥ 8.0 g/dl&#xD;
&#xD;
               4. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 1.5 x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min (Cockcroft-Gault&#xD;
                  calculation)&#xD;
&#xD;
               6. Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               7. Serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of&#xD;
                  normal (LLN) (treatment of hypercalcemia is allowed and subject may enroll if&#xD;
                  hypercalcemia returns to normal with standard treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received chemotherapy, immunomodulatory drugs (e.g., lenalidomide,&#xD;
             thalidomide or pomalidomide), immunotherapy, radiation therapy, or any investigational&#xD;
             drug(s) within 14 days before enrollment or who have not recovered from the side&#xD;
             effects of the therapy to at least grade 1. Localized radiation therapy to a single&#xD;
             site within 7 days is acceptable.&#xD;
&#xD;
          -  Prior therapy with a heat shock protein 90 (HSP90) inhibitor.&#xD;
&#xD;
          -  Daily requirement for corticosteroids (except for inhalational corticosteroids);&#xD;
             prednisone ≤ 10mg/day or equivalent is permitted for other medical conditions.&#xD;
&#xD;
          -  Prior peripheral stem cell transplant within 12 weeks of the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Use of venous access devices made of materials other than silicone for the infusion of&#xD;
             ganetespib. Patients with these devices are eligible as long as the device is not used&#xD;
             for the infusion.&#xD;
&#xD;
          -  History of severe allergic or hypersensitivity reactions to excipients (e.g.,&#xD;
             Polyethylene glycol [PEG] 300 and Polysorbate 80).&#xD;
&#xD;
          -  Baseline corrected QT interval (QTc) &gt; 470 msec or previous history of QT prolongation&#xD;
             while taking other medications.&#xD;
&#xD;
          -  Ventricular ejection fraction (Ef) ≤ 50 % at baseline.&#xD;
&#xD;
          -  History of documented congestive heart failure (CHF), New York Heart Association class&#xD;
             II/III/IV, with a history of dyspnea, orthopnea or edema that requires current&#xD;
             treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor&#xD;
             blockers, beta-blockers or diuretics. NOTE: Use of these medications for the treatment&#xD;
             of hypertension is allowed.&#xD;
&#xD;
          -  High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade&#xD;
             atrioventricular [AV]-block, supra-ventricular arrhythmias which are not adequately&#xD;
             rate-controlled) that require current treatment with the following anti-arrythmic&#xD;
             drugs: flecainide, moricizine or propafenone.&#xD;
&#xD;
          -  History of active current coronary artery disease or unstable angina.&#xD;
&#xD;
          -  Peripheral neuropathy ≥ grade 2.&#xD;
&#xD;
          -  Treatment with chronic immunosuppressants (e.g., cyclosporine following&#xD;
             transplantation).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, human&#xD;
             immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral&#xD;
             therapy, severe or systemic infection, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
          -  Other medications, or severe acute/chronic medical or psychiatric condition, or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration, or may interfere with the interpretation of study&#xD;
             results, and in the judgment of the investigator would make the subject inappropriate&#xD;
             for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sagar Lonial, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Sagar Lonial</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Velcade</keyword>
  <keyword>Ganetespib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

